

# Contents

<b>1</b>	<b>Statistical Models and Methods for Incomplete Data in Randomized Clinical Trials.....</b>	<b>1</b>
	Michael A. McIsaac and Richard J. Cook	
<b>2</b>	<b>Bayesian Decision Theory and the Design and Analysis of Randomized Clinical Trials.....</b>	<b>29</b>
	Andrew R. Willan	
<b>3</b>	<b>Designing Multi-arm Multi-stage Clinical Studies.....</b>	<b>51</b>
	Thomas Jaki	
<b>4</b>	<b>Statistical Approaches to Improving Trial Efficiency and Conduct.....</b>	<b>71</b>
	Janice Pogue, P.J. Devereaux, and Salim Yusuf	
<b>5</b>	<b>Competing Risks and Survival Analysis .....</b>	<b>85</b>
	Kees van Montfort, Peter Fennema, and Wendimagegn Ghidey	
<b>6</b>	<b>Recent Developments in Group-Sequential Designs .....</b>	<b>97</b>
	James M.S. Wason	
<b>7</b>	<b>Statistical Inference for Non-inferiority of a Diagnostic Procedure Compared to an Alternative Procedure, Based on the Difference in Correlated Proportions from Multiple Raters.....</b>	<b>119</b>
	Hiroyuki Saeki and Toshiro Tango	
<b>8</b>	<b>Design and Analysis of Clinical Trial Simulations .....</b>	<b>139</b>
	Kazuhiko Kuribayashi	
<b>9</b>	<b>Causal Effect Estimation and Dose Adjustment in Exposure-Response Relationship Analysis .....</b>	<b>153</b>
	Jixian Wang	

<b>10</b>	<b>Different Methods to Analyse the Results of a Randomized Controlled Trial with More Than One Follow-Up Measurement .....</b>	<b>177</b>
	Jos W.R. Twisk	
<b>11</b>	<b>Statistical Methods for the Assessment of Clinical Relevance .....</b>	<b>195</b>
	Meinhard Kieser	
<b>12</b>	<b>Statistical Considerations in the Use of Composite Endpoints in Time to Event Analyses .....</b>	<b>209</b>
	Richard J. Cook and Ker-Ai Lee	
<b>13</b>	<b>Statistical Validation of Surrogate Markers in Clinical Trials .....</b>	<b>227</b>
	Ariel Alonso, Geert Molenberghs, and Gerard van Breukelen	
<b>14</b>	<b>Biomarker-Based Designs of Phase III Clinical Trials for Personalized Medicine .....</b>	<b>247</b>
	Shigeyuki Matsui, Takahiro Nonaka, and Yuki Choai	
<b>15</b>	<b>Dose-Finding Methods for Two-Agent Combination Phase I Trials .....</b>	<b>265</b>
	Akihiro Hirakawa and Shigeyuki Matsui	
<b>16</b>	<b>Multi-state Models Used in Oncology Trials.....</b>	<b>283</b>
	Birgit Gaschler-Markefski, Karin Schiefele, Julia Hocke, and Frank Fleischer	
<b>17</b>	<b>Review of Designs for Accommodating Patients' or Physicians' Preferences in Randomized Controlled Trials .....</b>	<b>305</b>
	Afisi S. Ismaila and Stephen D. Walter	
<b>18</b>	<b>Dose Finding Methods in Oncology: From the Maximum Tolerated Dose to the Recommended Phase II Dose .....</b>	<b>335</b>
	Xavier Paoletti and Adélaide Doussau	